# OnCo record paper-litespark-011-motzer-lancet-2026 (paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/key-papers/paper-litespark-011-motzer-lancet-2026/>
  a schema:ScholarlyArticle ;
  onco:kind "paper" ;
  schema:identifier "paper-litespark-011-motzer-lancet-2026" ;
  schema:name "Belzutifan plus lenvatinib versus cabozantinib in patients with previously treated advanced renal cell carcinoma (LITESPARK-011): an open-label, randomised, controlled, phase 3 trial"@en ;
  schema:description "In 747 people whose advanced clear-cell kidney cancer had grown after immunotherapy, belzutifan plus lenvatinib kept the cancer from progressing for a median of 14.8 months against 10.7 with cabozantinib, but at this interim look the survival difference was not statistically significant."@en ;
  schema:url <https://onco.cc/key-papers/paper-litespark-011-motzer-lancet-2026/> ;
  schema:dateModified "2026-09-24"^^xsd:date ;
  schema:citation <https://doi.org/10.1016/S0140-6736(26)01089-5>, <https://pubmed.ncbi.nlm.nih.gov/42586114/>, <https://clinicaltrials.gov/study/NCT04586231> ;
  schema:sameAs <https://doi.org/10.1016/S0140-6736(26)01089-5> ;
  schema:datePublished "2026"^^xsd:gYear ;
  schema:author "Motzer RJ, McDermott R, Park SH, et al." ;
  onco:cancers <https://onco.cc/cancers/rcc/> ;
  onco:drugs <https://onco.cc/drugs/belzutifan/>, <https://onco.cc/drugs/lenvatinib/>, <https://onco.cc/drugs/cabozantinib/> ;
  onco:companies <https://onco.cc/companies/merck/>, <https://onco.cc/companies/eisai/> ;
  onco:trials <https://onco.cc/trials/nct04586231/> ;
  onco:people <https://onco.cc/people/robert-motzer/> ;
  onco:journals <https://onco.cc/journals/lancet/> .